NCT01940172 - Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions

Relapsed Epithelial Ovarian CancerRelapsed Primary Peritoneal CancerRelapsed Fallopian Tube Cancer

Interventions

DRUG

Birinapant

"Dose Escalation:~Dose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks );"

DRUG

Conatumumab

10 mg/kg IV on Day 1 and 15 of each cycle

Trial Locations (9)

19107

TetraLogic Research Site, Philadelphia

19111

TetraLogic Research Site, Philadelphia

27710

TetraLogic Research Site, Durham

37203

TetraLogic Research Site, Nashville

39720

TetraLogic research site, Fresno

66205

TetraLogic Research Site, Fairway

75201

TetraLogic Research Facility, Dallas

93401

TetraLogic Research Site, San Luis Obispo

02114

TetraLogic Research Site, Boston